Drug combinations can be the prime strategy for increasing the initial treatment options in cancer therapy. However, identifying the combinations through experimental approaches is very laborious and costly. Notably, in vitro and/or in vivo examination of all the possible combinations might not be plausible. This study presented a novel computational approach to predicting synergistic drug combinations. Specifically, the deep neural network-based binary classification was utilized to develop the model. Various physicochemical, genomic, protein-protein interaction and protein-metabolite interaction information were used to predict the synergy effects of the combinations of different drugs. The performance of the constructed model was compared with shallow neural network (SNN), k-nearest neighbors (KNN), random forest (RF), support vector machines (SVMs), and gradient boosting classifiers (GBC). Based on our findings, the proposed deep neural network model was found to be capable of predicting synergistic drug combinations with high accuracy. The prediction accuracy and AUC metrics for this model were 92.21% and 97.32% in tenfold cross-validation. According to the results, the integration of different types of physicochemical and genomics features leads to more accurate prediction of synergy in cancer drugs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105711 | PMC |
http://dx.doi.org/10.1038/s41598-023-33271-3 | DOI Listing |
BMC Oral Health
January 2025
Department of Endodontics, Faculty of Dentistry, Erciyes University, Kayseri, Turkey.
Background: This study assessed stress distributions in simulated mandibular molars filled with various materials after the removal of fractured instruments from the apical thirds of the root canals.
Methods: Finite element models of the mesial and distal root canals were created, where fractured instruments were assumed to be removed using a staging platform established with a modified Gates-Glidden bur (Woodpecker, Guangxi, P.R.
BMC Oral Health
January 2025
Faculty of Dentistry, Department of Endodontics, Ondokuz Mayis University, Samsun, Kurupelit, 55139, Turkey.
Background: The aim was to evaluate the stresses in teeth, with external root resorption (ERR) restored with different materials using finite element analysis (FEA).
Methods: In this study, a Micro-CT scan was conducted on a prepared maxillary central tooth. DICOM-compatible images obtained from the sections were converted into stereolithography format using Ctan software.
Sci Rep
January 2025
Department of Conservative Dentistry and Endodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, 600077, India.
Polydopamine (PD), inspired by the wet adhesion mechanism of mussel foot proteins, has emerged as a promising adhesive material with wide-ranging applications. This study aimed to compare the adhesive properties of PD and Glass Ionomer Cement (GIC) on enamel and dentin substrates, evaluating PD's potential as an alternative adhesive in dental practice. A total of 120 human premolars were prepared, with 80 teeth allocated for Scanning Electron Microscopy (SEM) analysis and 40 teeth reserved for shear bond strength testing.
View Article and Find Full Text PDFClinical trials demonstrate the short-term efficacy of dual CFTR modulators, but long-term real-world data is limited. We aimed to investigate the effects of 24-month lumacaftor/ivacaftor (LUM/IVA) therapy in pediatric CF patients (pwCF). This observational study included pwCF homozygous for F508del mutation treated between 2021 and 2023.
View Article and Find Full Text PDFClin Breast Cancer
December 2024
Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.
Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.
Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!